The $26,500 Mirage: Why the New Alzheimer’s Drugs Are Mostly Just Bureaucracy

Leqembi and Kisunla promise to slow down cognitive decline, but the reality is a punishing gauntlet of biweekly infusions, brain bleeds, and a system built to say no.

Imagine spending four hours every other Tuesday in a sterile hospital room, watching a clear liquid drip into your 78-year-old mother’s arm. You do this because you were told this drug, Leqembi, is a historic breakthrough that fights Alzheimer's. What they did not tell you is that after eighteen months of this routine, your mother will likely end up with about five months of delayed decline, a bank account drained by thousands of dollars in co-pays, and a brain that requires constant monitoring for microbleeds.

More from Care Navigation →   ·   Back to Perch   ·   Browse all stories